



Exelixis to Release Third Quarter 2018 Financial Results on Thursday, November 1, 2018

October 18, 2018

– Conference Call and Webcast to Follow at 5:00 p.m. EDT/ 2:00 p.m. PDT –

ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 18, 2018-- [Exelixis, Inc.](#) (NASDAQ: EXEL) announced today that its third quarter 2018 financial results will be released on Thursday, November 1, 2018 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website.

To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company's website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 855-793-2457 (domestic) or 631-485-4921 (international) and provide the conference call passcode 1043999 to join by phone.

A telephone replay will be available until 8:00 p.m. EDT on November 3, 2018. Access numbers for the telephone replay are: 855-859-2056 (domestic) and 404-537-3406 (international); the passcode is 1043999. A webcast replay will also be archived on www.exelixis.com for one year.

About Exelixis

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model genetic systems, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. We discovered our three commercially available products, CABOMETRYX[®] (cabozantinib), COMETRIQ[®] (cabozantinib) and COTELLIC[®] (cobimetinib), and have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery – all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. In July 2018, Exelixis was added to the Standard & Poor's (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. For more information about Exelixis, please visit www.exelixis.com, follow [@ExelixisInc](#) on Twitter or like [Exelixis, Inc.](#) on Facebook.

Exelixis and the Exelixis logo are registered U.S. trademarks.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20181018005903/en/>

Source: Exelixis, Inc.

Exelixis, Inc.

Susan Hubbard, 650-837-8194

Executive Vice President, Public Affairs & Investor Relations

shubbard@exelixis.com